MRNA — Moderna, Inc.

Summary of Moderna's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $400 million for Q1 2026, a significant increase of $300 million year-over-year, primarily driven by international sales under long-term partnerships.
• Net Loss: Reported at $1.3 billion (or $3.40 per share), which includes an $878 million litigation settlement. Excluding this, the adjusted net loss was $0.5 billion ($1.18 per share), down over 50% from the previous year.
• Cash and Investments: Ended the quarter with $7.5 billion, down from $8.1 billion at the end of 2025, primarily due to operating losses.
• Cost Reduction: Achieved a 26% year-over-year reduction in adjusted cash costs, maintaining a target of approximately $4.2 billion for the full year.

2. Strategic Updates and Business Highlights

• Product Approvals: Received EU approval for the first flu plus COVID combination vaccine (mCOMBRIAX) and a new respiratory vaccine (mNEXSPIKE), marking a total of four approved products.
• Clinical Trials: Initiated a Phase III trial for Intismeran in non-small cell lung cancer and advanced several other oncology and rare disease programs.
• Geographic Expansion: Strong revenue performance from international markets, with a focus on long-term strategic partnerships in the U.K., Canada, and Australia.

3. Forward Guidance and Outlook

• Revenue Growth: Reiterating guidance for up to 10% revenue growth in 2026, with expectations of $50 million to $100 million in Q2 revenue.
• Cost of Sales: Projected to increase to $1.8 billion, including the litigation settlement charge, but expected to improve gross margins through manufacturing efficiencies.
• R&D and SG&A Expenses: Anticipated to remain at approximately $3 billion and $1 billion, respectively, with a focus on disciplined spending.

4. Bad News, Challenges, or Points of Concern

• Litigation Settlement: The $950 million payment due in Q3 2026 raises concerns about cash flow and potential additional liabilities of up to $1.3 billion, although management believes these are not probable.
• Market Risks: Potential declines in COVID vaccination rates could impact revenue, although this is expected to be offset by growth in other product lines.
• Geopolitical Factors: Ongoing conflicts, particularly in the Middle East, are being monitored for potential impacts on financial outlook, though no material effects are currently anticipated.

5. Notable Q&A Insights

• Intismeran Strategy: The Phase III study for Intismeran in lung cancer aims to demonstrate efficacy as a monotherapy and in combination with KEYTRUDA, focusing on early-stage disease intervention.
• Revenue Recognition: Discussions on how revenue from Intismeran will be recognized, with an emphasis on ensuring a fair profit split with Merck.
• Flu Vaccine Outlook: The upcoming PDUFA date for the flu vaccine (mRNA-1010) is set for August 5, 2026, with ongoing positive interactions with the FDA.
• Market Access for New Products: Emphasis on securing pricing and reimbursement for the new combination vaccine in Europe, with a focus on demonstrating its value to healthcare systems.

Overall, Moderna reported a strong start to 2026 with significant revenue growth and strategic advancements, despite challenges related to litigation and market dynamics. The company remains optimistic about its pipeline and future revenue potential.